Palantir's Post-Earnings Rally Faces a Reality Check From Insider Sales and European Scrutiny
Published on 08/06/2026 at 22:01 | Redaktion boerse-global.de
The euphoria surrounding Palantir Technologies' blockbuster second-quarter results is colliding with a more sobering set of concerns — from executives cashing out at the peak of the rally to fresh questions about data sovereignty in Europe.
Shares of the Denver-based data analytics firm were trading around €134.84 on Thursday, down 1.72 percent from the prior session's close, as investors took some profits off the table following a dramatic 30 percent surge on Tuesday — the stock's biggest one-day move since early 2024. The pullback, however modest, underscores the tension between the company's extraordinary operational performance and the mounting skepticism about its valuation and governance.
The Numbers Behind the Noise
Palantir's second-quarter results, released Monday, were nothing short of spectacular. Revenue hit $1.935 billion, a 93 percent year-over-year jump that blew past the consensus estimate of $1.81 billion. US commercial revenue surged 149 percent to $764 million, while GAAP net income came in at $1.06 billion. The company also raised its full-year 2026 revenue guidance to $8.15 billion, up from a prior range of $7.65 billion to $7.66 billion, citing what executives described as "out-of-this-world" demand for its AIP analytics platform.
Digging deeper into the operational metrics reveals even more impressive figures. Total contract value (TCV) reached a record $3.373 billion for the quarter, with US commercial TCV alone climbing 153 percent year-over-year to $2.132 billion. The company's "Rule of 40" score — a benchmark measuring the balance between growth and profitability — hit 155 percent, while the adjusted free cash flow margin stood at 63 percent, translating to $1.22 billion in free cash flow.
Should investors sell immediately? Or is it worth buying Palantir?
New business wins added further momentum: a $500 million expanded partnership with law firm Kirkland & Ellis, a $300 million framework agreement with the US Department of Agriculture, and a partnership with USA Today Co. announced Wednesday to use Palantir's AI software for reader data analysis and monetization automation, as reported by Poynter.
Insider Selling Raises Eyebrows
Yet even as the company celebrated its record quarter, a wave of insider selling has given some investors pause. CEO Alex Karp and other directors reportedly offloaded more than $150 million worth of stock within 72 hours of the earnings release, according to regulatory filings cited by media reports. The sales came during a rally that lifted the stock 27.79 percent over seven days.
Karp had previously sold $54 million worth of shares in May, while co-founder Stephen Cohen disposed of $43.5 million in the same month. Technology chief Shyam Sankar sold 185,000 shares for roughly $24 million on July 2, and board member Alexander D. Moore offloaded another 16,000 shares on July 15 under a pre-arranged trading plan.
Insider sales following strong earnings are often routine — frequently tied to diversification strategies or predetermined plans. But the timing of these transactions, right in the middle of the post-earnings euphoria, raises legitimate questions about whether management believes the stock's near-term upside is fully priced in.
European Headwinds Mount
Beyond the insider activity, Palantir faces growing resistance in Europe on multiple fronts. The Financial Times reported Thursday that at least six senior officials at NHS England have disclosed financial or professional ties to Palantir, intensifying scrutiny of the £330 million Federated Data Platform (FDP) contract, which is up for renewal.
This follows a series of other European setbacks. London Mayor Sadiq Khan halted a planned £50 million AI contract between the Metropolitan Police and Palantir in May, citing transparency and procurement ethics concerns. In February, 37 members of the UK Parliament signed a motion demanding full transparency regarding a £240 million contract the Ministry of Defence awarded directly to Palantir in December 2025. Critics also raised concerns in May that a data deal with the UK's Financial Conduct Authority could expose British financial data to US authorities.
Perhaps most troubling for Palantir's European ambitions, defense agencies in Switzerland and Germany have reportedly rejected contract offers after risk assessments concluded that the company's architecture cannot technically rule out access by US intelligence agencies under the US CLOUD Act. For a company increasingly reliant on government and military contracts for growth, this trust deficit in security-sensitive European markets could prove more damaging than in the US.
The Valuation Debate Rages On
Wall Street, for its part, has responded to the results with a wave of price target hikes. Citigroup raised its target from $200 to $245 on Tuesday and reaffirmed its buy rating, reversing a downgrade it had issued in late July on valuation grounds. Deutsche Bank upgraded the stock from Hold to Buy the same day, calling the quarterly results "extraordinary." Other firms including DA Davidson, Truist, Piper Sandler, UBS, and Mizuho followed with increased targets ranging from $200 to $230.
Analyst price targets now span a wide range, from $70 to $255. Morningstar, which confirmed its "Narrow Moat" rating on July 30, pegged fair value at $153 and flagged "very high" uncertainty about how competing AI models might erode Palantir's technological edge over time.
Palantir at a turning point? This analysis reveals what investors need to know now.
The valuation math remains the central point of contention. The stock's price-to-sales ratio based on expected revenue stood at 34.59 at the end of July — a level that has sparked intense debate among analysts. At that multiple, any deceleration in the US commercial growth rate would likely be punished disproportionately.
Institutional investors remain broadly engaged, with 4,175 institutional owners holding approximately 1.75 billion shares as of late July, led by BlackRock and Vanguard. That signals continued confidence from large players in the long-term story, even after the recent surge.
What Comes Next
The stock currently trades about 25 percent below its November 3, 2025 high, a reminder of how quickly sentiment can shift for a stock trading at such an elevated multiple. The immediate catalyst to watch is the decision on the NHS contract renewal, while the next quarterly report will reveal whether the AIP growth trajectory is sustainable or whether valuation critics will be vindicated.
For now, Palantir presents a study in contradictions: fundamentals that are arguably the strongest in its history, juxtaposed against insider selling at the top, European distrust, and a valuation that leaves little room for error. The bulls see a company whose raised guidance may still prove conservative if demand remains "out of this world." The bears see a stock priced for perfection in an environment where political and regulatory risks are multiplying. Both sides have data on their side — which is precisely why the debate is unlikely to be settled anytime soon.
Ad
Palantir Stock: New Analysis - 6 August
Fresh Palantir information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
